Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
Date:6/9/2009

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans by Isis and its collaborators. Isis' scientists presented new preclinical data on ISIS-SGLT2Rx showing a robust and sustained reduction in sodium dependent glucose co-transporter type 2 (SGLT2) levels that resulted in a significant reduction in blood glucose levels in multiple animal species. Isis and its collaborators also presented data on a number of other promising new targets demonstrating that reducing levels of these targets with antisense drugs can significantly lower blood glucose levels and increase the body's sensitivity to insulin. Additionally, data was presented from Isis' anti-obesity drug discovery program showing antisense drugs reduced fat mass and body weight in animals by reducing levels of targets in peripheral tissues such as liver and fat without affecting the central nervous system, further validating Isis' anti-obesity therapeutic strategy.

In the oral presentation titled "ISIS 388626, an SGLT2 Antisense Drug, Causes Robust and Sustained Glucosuria in Multiple Species and is Safe and Well-Tolerated," Dr. Sanjay Bhanot highlighted data that demonstrated that antisense reduction of SGLT2, a key transporter involved in glucose re-absorption in the kidney, produced the following results in preclinical models:

  • Dose-dependent reduction in kidney levels of SGLT2 with >75% reduction at the highest dose accompanied by a significant increase (>100-fold) in glucose excretion in the urine in multiple species including monkeys
  • Secondary improvemen
    '/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... 27 Global pharmaceutical outsourcing has become ... supply chain environment that has pharmaceutical and life sciences ... co-sponsored by PwC US and published today by Axendia, ... the report, 50 percent of pharmaceutical and life sciences ...
... Essential Pharmaceuticals, LLC, a private company dedicated to ... sciences market, announced today that the Company will ... products: serum replacement, cryopreservation and clinical pathology media, ... Cell-Ess™ Serum Replacement cell culture medium, ...
Cached Medicine Technology:As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 2As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 3As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 4As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 5Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical 2
(Date:8/1/2014)... Stress management can be difficult in this day and ... diminish rest and leisure time, stress can mount up and ... a way to manage stress in order to be healthy ... good sense of work-life balance is the key to managing ... of SF Custom Chiropractic. “Stress, left unchecked, can not only ...
(Date:8/1/2014)... 2014 iFitDress.com, a professional company of ... collection of 2014 silver bridesmaid dresses recently. ... to the latest fashion trends. What’s more, they are ... percent off. , iFitDress.com is one of the ... not only silver bridesmaid gowns, but also many other ...
(Date:7/31/2014)... July 31, 2014 Serious buyer, Andrew ... Acid Test concert posters. Owsley Bear Stanley, the King ... the Grateful Dead. According to Hawley, “The Grateful Dead ... acid test parties in San Francisco and Los Angeles ... on three different colors of paper. They were a ...
(Date:7/31/2014)... birth control pills containing high-dose estrogen and a few ... whereas women using some other formulations did not, according ... journal of the American Association for Cancer Research. , ... [birth control pills] in the past year is associated ... or former oral contraceptive use, and that this risk ...
(Date:7/31/2014)... The 2013 PolyU TSI hit a record ... in 2012. The index measures inbound tourists’ satisfaction ... into an overall index. The 2013 index indicates ... Hong Kong over time. , The index shows ... in Hong Kong are attractions (79.27) and transportation ...
Breaking Medicine News(10 mins):Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... the Journal of Hospital Medicine , the risk ... upon general medicine inpatients and those with at least ... factors such as having cancer, chronic diseases such as ... medications, the studies identified other factors which increase the ...
... drugs that target specific molecular mechanisms of cancer have improved ... benefits may come with a cost to the patient,s sex ... the European Society for Medical Oncology (ESMO) in Milan, Italy, ... investigate the impact of cancer therapy on the sexual functioning ...
... Dr. David Nabarro, Assistant Secretary-General at the United Nations and ... Food Security Crisis, will deliver the keynote address at the ... Security on Tuesday, Oct. 19, 5 p.m., at Centre Mont-Royal, ... offer a global perspective on prospects for food and nutrition ...
... HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay News) -- ... just as well as those who receive more, new research ... among U.S. hospitals. The studies are published in the ... Medical Association . In the first study, researchers in ...
... virusrelated virus (XMRV) has been the subject of many ... have created an unclear picture of XMRV,s role in ... November 15 issue of The Journal of Infectious ... possible link between XMRV and prostate cancer but not ...
... a synthetic molecule they designed can block activation of a ... some of those cancer cells to survive chemotherapy. ... cells appear to be protected from the toxic effects of ... protein from protecting the cells, the research suggests. As a ...
Cached Medicine News:Health News:Hospital readmission studies: Influencing factors identified 2Health News:Hospital readmission studies: Influencing factors identified 3Health News:Sexual issues a major concern for cancer patients taking new targeted drugs 2Health News:Coordinator of UN high-level task force to open McGill Food Security Conference 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3
Versatrek 528 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
ELP 40- 8 Way Head Strip Plate Washer....
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
Medicine Products: